Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

BACKGROUND. TGF-β has potent profibrotic activity in vitro and has long been implicated in systemic sclerosis (SSc), as expression of TGF-β–regulated genes is increased in the skin and lungs of patients with SSc. Therefore, inhibition of TGF-β may benefit these patients. METHODS. Patients with early...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Invest
Κύριοι συγγραφείς: Rice, Lisa M., Padilla, Cristina M., McLaughlin, Sarah R., Mathes, Allison, Ziemek, Jessica, Goummih, Salma, Nakerakanti, Sashidhar, York, Michael, Farina, Giuseppina, Whitfield, Michael L., Spiera, Robert F., Christmann, Romy B., Gordon, Jessica K., Weinberg, Janice, Simms, Robert W., Lafyatis, Robert
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society for Clinical Investigation 2015
Θέματα:
Clinical Medicine
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4563675/
https://ncbi.nlm.nih.gov/pubmed/26098215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI77958
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια